Roivant Sciences (ROIV) Resumen de Acciones
Roivant Sciences Ltd., empresa biofarmacéutica en fase clínica, se centra en el descubrimiento, desarrollo y comercialización de medicamentos y tecnologías. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en ROIV a partir de nuestros controles de riesgos.
ROIV Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10
FV
273.7% sobrevalorado descuento intrínseco60
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Competidores de Roivant Sciences Ltd.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$37.37 |
| Máximo en las últimas 52 semanas | US$37.46 |
| Mínimo de 52 semanas | US$11.54 |
| Beta | 1.13 |
| Cambio en 1 mes | 8.29% |
| Variación en 3 meses | 15.30% |
| Cambio de 1 año | 217.77% |
| Variación en 3 años | 235.16% |
| Variación en 5 años | 277.86% |
| Variación desde la OPV | 259.33% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 17
ROIV: 2026 Autoimmune And Cardiopulmonary Readouts Will Drive Bullish Repricing
Roivant Sciences has its analyst fair value estimate updated from $39.04 to $41.82 as analysts lift price targets toward the mid to high $40s, citing refreshed models after recent earnings, Q1 updates, and a pipeline that is viewed as having multiple upcoming catalysts. Analyst Commentary Recent Street research on Roivant Sciences has clustered around higher fair value targets and updated models after Q1 and prior fiscal Q4 results.Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • Aug 17
ROIV: 2026 Autoimmune And Cardiopulmonary Readouts Will Drive Bullish Repricing
Roivant Sciences has its analyst fair value estimate updated from $39.04 to $41.82 as analysts lift price targets toward the mid to high $40s, citing refreshed models after recent earnings, Q1 updates, and a pipeline that is viewed as having multiple upcoming catalysts. Analyst Commentary Recent Street research on Roivant Sciences has clustered around higher fair value targets and updated models after Q1 and prior fiscal Q4 results.Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 03
ROIV: Late Stage Data Catalysts Will Drive Future Upside Potential
Roivant Sciences' updated analyst price target has shifted to $42, with analysts citing refreshed models after recent earnings, pipeline updates, and IMVT-1402 trial data as key drivers behind the change from the prior $45 view. Analyst Commentary Recent Street research on Roivant Sciences has leaned constructive, with several bullish analysts revising their models after earnings, pipeline updates, and new IMVT-1402 data.
Actualización de narrativa • Jul 20
ROIV: Future Drug Launches And Legal Settlement Shape Balanced Risk Profile
Roivant Sciences' analyst price target has moved from $21.00 to $31.50, with analysts pointing to refreshed models after recent earnings, updated pipeline views, and new clinical data as key drivers of their revised assumptions. Analyst Commentary Recent research updates on Roivant Sciences show that many firms are lifting their price targets following earnings and new clinical data, but the tone is not uniformly bullish.
Nueva narrativa • Jul 19
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
The "Roivant Compounding Fantasy" relies on a lazy sum-of-the-parts calculation, treating binary litigation windfalls and a crowded autoimmune pipeline as a bulletproof thesis. Here is why the market is mispricing the structural friction inside Roivant's hub-and-spoke model: 1.Actualización de narrativa • Jul 06
ROIV: Late Stage Pipeline Progress Will Shape Future Upside Potential
Roivant Sciences' analyst fair value estimate has increased from $32.31 to $45.00 as analysts update their models following recent earnings, pipeline data, and revised assumptions on revenue growth, margins, and future P/E levels. Analyst Commentary Recent Street research on Roivant Sciences points to a cluster of higher fair value views, with several bullish analysts revisiting their models after earnings updates and new clinical data.Actualización de narrativa • Jun 22
ROIV: 2026 Autoimmune Readouts And Regulatory Milestones Will Drive Repricing
Analysts have raised their average price target on Roivant Sciences to $39.04, citing updated models following recent earnings, pipeline data, and revised assumptions regarding the discount rate, profit margin, and forward P/E. Analyst Commentary Recent research updates on Roivant Sciences point to a more constructive stance from several firms, with higher price targets tied to refreshed models following quarterly results, pipeline data and changes to key assumptions such as discount rates, profit margins and forward P/E multiples.Artículo de análisis • Jun 19
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...Actualización de narrativa • Jun 06
ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing
Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.Actualización de narrativa • May 19
ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts
Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.Actualización de narrativa • Apr 21
ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage Readouts
The updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.Actualización de narrativa • Apr 05
ROIV: Settlement Cash Will Refocus Story On 2026 Clinical Readouts
Analysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.Actualización de narrativa • Mar 22
ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout Repricing
Narrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.Actualización de narrativa • Mar 07
ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout Upside
Analysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.Actualización de narrativa • Feb 21
ROIV: 2026 Clinical Readouts Are Expected To Unlock Further Upside
Roivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.Actualización de narrativa • Feb 06
ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock Upside
Narrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.Actualización de narrativa • Jan 22
ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive Upside
Narrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.Actualización de narrativa • Jan 08
ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive Upside
Analysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.Actualización de narrativa • Dec 15
ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026
Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.Actualización de narrativa • Nov 30
ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And Beyond
The analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.Actualización de narrativa • Nov 16
ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares Higher
Analysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.Actualización de narrativa • Oct 31
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
The analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.Actualización de narrativa • Oct 17
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.Actualización de narrativa • Oct 03
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
The analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.Actualización de narrativa • Sep 18
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.Seeking Alpha • Apr 23
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Summary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha
Nueva narrativa • Jan 26
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Rentabilidad de los accionistas
| ROIV | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 6.0% | 1.8% | -0.3% |
| 1Y | 217.8% | 40.4% | 19.9% |
Rentabilidad vs. Industria: ROIV superó a la industria US Biotechs, que obtuvo un rendimiento del 40.4% el año pasado.
Rentabilidad vs. Mercado: ROIV superó al mercado US, que obtuvo un rendimiento del 19.9% el año pasado.
Volatilidad de los precios
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: ROIV no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ROIV (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 721 | Matt Gline | roivant.com |
Roivant Sciences Ltd., empresa biofarmacéutica en fase clínica, se dedica al descubrimiento, desarrollo y comercialización de medicamentos y tecnologías. Sus productos clínicos candidatos incluyen IMVT-1402, un anticuerpo monoclonal totalmente humano dirigido a FcRn en desarrollo para varias indicaciones autoinmunes mediadas por IgG; mosliciguat, un activador de sGC inhalado en desarrollo para la hipertensión pulmonar asociada a la enfermedad pulmonar intersticial; receptor cristalizable de fragmentos neonatales para el tratamiento de la enfermedad de graves, la artritis reumatoide difícil de tratar, la enfermedad de sjögren, la miastenia grave, la polineuropatía desmielinizante inflamatoria crónica y las indicaciones del lupus eritematoso cutáneo; batoclimab, un anticuerpo monoclonal totalmente humano para el tratamiento de la enfermedad ocular tiroidea; y brepocitinib, una potente molécula pequeña inhibidora de TYK2 y JAK1 en desarrollo para el tratamiento de la dermatomiositis, la uveítis no infecciosa, la sarcoidosis cutánea y otras enfermedades inmunomediadas. El principal programa de la empresa consiste en el mosliciguat, un activador inhalado de la sGC para el tratamiento de la hipertensión pulmonar asociada a la enfermedad pulmonar intersticial y otras enfermedades cardiopulmonares.
Resumen de fundamentos de Roivant Sciences Ltd.
| Estadísticas fundamentales de ROIV | |
|---|---|
| Capitalización bursátil | US$26.18b |
| Beneficios(TTM) | -US$266.25m |
| Ingresos (TTM) | US$7.53m |
3,584x
Ratio precio-ventas (PS)-101.4x
Ratio precio-beneficio (PE)¿Está ROIV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ROIV | |
|---|---|
| Ingresos | US$7.53m |
| Coste de los ingresos | US$731.42m |
| Beneficio bruto | -US$723.89m |
| Otros gastos | -US$457.64m |
| Beneficios | -US$266.25m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.37 |
| Margen bruto | -9,610.89% |
| Margen de beneficio neto | -3,534.96% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ROIV a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/18 09:36 |
| Precio de las acciones al final del día | 2026/08/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Roivant Sciences Ltd. está cubierta por 18 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Pickering | Bernstein |
| Jeffrey Walch | Bernstein |
| Chi Meng Fong | BofA Global Research |